Quantitative analysis of nanoparticle transport through in vitro blood-brain barrier models

被引:12
作者
Aberg, Christoffer [1 ]
机构
[1] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Groningen, Netherlands
关键词
biomolecular corona; blood-brain barrier; nanomedicine; nanoparticles; nanosafety; transwell systems;
D O I
10.1080/21688370.2016.1143545
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Nanoparticle transport through the blood-brain barrier has received much attention of late, both from the point of view of nano-enabled drug delivery, as well as due to concerns about unintended exposure of nanomaterials to humans and other organisms. In vitro models play a lead role in efforts to understand the extent of transport through the blood-brain barrier, but unique features of the nanoscale challenge their direct adaptation. Here we highlight some of the differences compared to molecular species when utilizing in vitro blood-brain barrier models for nanoparticle studies. Issues that may arise with transwell systems are discussed, together with some potential alternative methodologies. We also briefly review the biomolecular corona concept and its importance for how nanoparticles interact with the blood-brain barrier. We end with considering future directions, including indirect effects and application of shear and fluidics-technologies.
引用
收藏
页数:8
相关论文
共 97 条
[1]  
Abbott N.J., 2014, AAPS ADV PHARM SCI S, V10, P163, DOI [10.1007/978-1-4614-9105-7_6, DOI 10.1007/978-1-4614-9105-7_6]
[2]   Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy [J].
Aggarwal, Parag ;
Hall, Jennifer B. ;
McLeland, Christopher B. ;
Dobrovolskaia, Marina A. ;
McNeil, Scott E. .
ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (06) :428-437
[3]   Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26 [J].
Aktas, Y ;
Yemisci, M ;
Andrieux, K ;
Gürsoy, RN ;
Alonso, MJ ;
Fernandez-Megia, E ;
Novoa-Carballal, R ;
Quiñoá, E ;
Riguera, R ;
Sargon, MF ;
Çelik, HH ;
Demir, AS ;
Hincal, AA ;
Dalkara, T ;
Çapan, Y ;
Couvreur, P .
BIOCONJUGATE CHEMISTRY, 2005, 16 (06) :1503-1511
[4]  
ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44
[5]  
Andrieux K, 2009, J NANONEUROSCI, V1, P17
[6]   CHARACTERIZATION OF AN INVITRO BLOOD-BRAIN-BARRIER MODEL SYSTEM FOR STUDYING DRUG TRANSPORT AND METABOLISM [J].
AUDUS, KL ;
BORCHARDT, RT .
PHARMACEUTICAL RESEARCH, 1986, 3 (02) :81-87
[7]   Delivery of therapeutic agents to the central nervous system: the problems and the possibilities [J].
Begley, DJ .
PHARMACOLOGY & THERAPEUTICS, 2004, 104 (01) :29-45
[8]  
Bhabra G, 2009, NAT NANOTECHNOL, V4, P876, DOI [10.1038/NNANO.2009.313, 10.1038/nnano.2009.313]
[9]   Microfluidic organs-on-chips [J].
Bhatia, Sangeeta N. ;
Ingber, Donald E. .
NATURE BIOTECHNOLOGY, 2014, 32 (08) :760-772
[10]   Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1 [J].
Bhowmick, Tridib ;
Berk, Erik ;
Cui, Xiumin ;
Muzykantov, Vladimir R. ;
Muro, Silvia .
JOURNAL OF CONTROLLED RELEASE, 2012, 157 (03) :485-492